Adiponectin as an anti-inflammatory factor

Wellen, 2003, Obesity-induced inflammatory changes in adipose tissue, J Clin Invest, 112, 1785, 10.1172/JCI20514 Ouchi, 2003, Obesity, adiponectin and vascular inflammatory disease, Curr Opin Lipidol, 14, 561, 10.1097/00041433-200312000-00003 Berg, 2005, Adipose tissue, inflammation, and cardiovascular disease, Circ Res, 96, 939, 10.1161/01.RES.0000163635.62927.34 Hu, 1996, AdipoQ is a novel adipose-specific gene dysregulated in obesity, J Biol Chem, 271, 10697, 10.1074/jbc.271.18.10697 Maeda, 1996, cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1), Biochem Biophys Res Commun, 221, 286, 10.1006/bbrc.1996.0587 Scherer, 1995, A novel serum protein similar to C1q, produced exclusively in adipocytes, J Biol Chem, 270, 26746, 10.1074/jbc.270.45.26746 Arita, 1999, Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity, Biochem Biophys Res Commun, 257, 79, 10.1006/bbrc.1999.0255 Lusis, 2000, Atherosclerosis, Nature, 407, 233, 10.1038/35025203 Ouchi, 1999, Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin, Circulation, 100, 2473, 10.1161/01.CIR.100.25.2473 Kobashi, 2005, Adiponectin inhibits endothelial synthesis of interleukin-8, Circ Res, 97, 1245, 10.1161/01.RES.0000194328.57164.36 Ouchi, 2000, Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway, Circulation, 102, 1296, 10.1161/01.CIR.102.11.1296 Ouedraogo, 2006, Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway, Diabetes, 55, 1840, 10.2337/db05-1174 Ouchi, 2001, Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages, Circulation, 103, 1057, 10.1161/01.CIR.103.8.1057 Yokota, 2000, Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages, Blood, 96, 1723, 10.1182/blood.V96.5.1723 Wulster-Radcliffe, 2004, Adiponectin differentially regulates cytokines in porcine macrophages, Biochem Biophys Res Commun, 316, 924, 10.1016/j.bbrc.2004.02.130 Yamaguchi, 2005, Adiponectin inhibits toll-like receptor family-induced signaling, FEBS Lett, 579, 6821, 10.1016/j.febslet.2005.11.019 Kumada, 2004, Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages, Circulation, 109, 2046, 10.1161/01.CIR.0000127953.98131.ED Choi, 2007, Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome, Diabetes Res Clin Pract, 75, 235, 10.1016/j.diabres.2006.06.019 Okamoto, 2002, Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice, Circulation, 106, 2767, 10.1161/01.CIR.0000042707.50032.19 Yamauchi, 2003, Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis, J Biol Chem, 278, 2461, 10.1074/jbc.M209033200 Waltenberger, 2001, Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications, Cardiovasc Res, 49, 554, 10.1016/S0008-6363(00)00228-5 Warley, 1995, Capillary surface area is reduced and tissue thickness from capillaries to myocytes is increased in the left ventricle of streptozotocin-diabetic rats, Diabetologia, 38, 413, 10.1007/BF00410278 Noon, 1997, Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure, J Clin Invest, 99, 1873, 10.1172/JCI119354 Yilmaz, 2003, Obesity is associated with impaired coronary collateral vessel development, Int J Obes Relat Metab Disord, 27, 1541, 10.1038/sj.ijo.0802474 Lind, 1993, Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia, and hyperinsulinemia, Am Heart J, 125, 1494, 10.1016/0002-8703(93)90446-G Steinberg, 1996, Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance, J Clin Invest, 97, 2601, 10.1172/JCI118709 Al Suwaidi, 2001, Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries, J Am Coll Cardiol, 37, 1523, 10.1016/S0735-1097(01)01212-8 Ouchi, 2004, Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells, J Biol Chem, 279, 1304, 10.1074/jbc.M310389200 Chen, 2003, Adiponectin stimulates production of nitric oxide in vascular endothelial cells, J Biol Chem, 278, 45021, 10.1074/jbc.M307878200 Hattori, 2003, Globular adiponectin upregulates nitric oxide production in vascular endothelial cells, Diabetologia, 46, 1543, 10.1007/s00125-003-1224-3 Motoshima, 2004, Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL, Biochem Biophys Res Commun, 315, 264, 10.1016/j.bbrc.2004.01.049 Xi, 2005, Stimulated HSP90 binding to eNOS and activation of the PI3-Akt pathway contribute to globular adiponectin-induced NO production: vasorelaxation in response to globular adiponectin, Biochem Biophys Res Commun, 332, 200, 10.1016/j.bbrc.2005.04.111 Moncada, 1991, Nitric oxide: physiology, pathophysiology and pharmacology, Pharmacol Rev, 43, 109 Ohashi, 2006, Adiponectin replenishment ameliorates obesity-related hypertension, Hypertension, 47, 1108, 10.1161/01.HYP.0000222368.43759.a1 Ouchi, 2003, Association of hypoadiponectinemia with impaired vasoreactivity, Hypertension, 42, 231, 10.1161/01.HYP.0000083488.67550.B8 Shibata, 2004, Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling, J Biol Chem, 279, 28670, 10.1074/jbc.M402558200 Kobayashi, 2004, Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin, Circ Res, 94, e27, 10.1161/01.RES.0000119921.86460.37 Lin, 2004, Angiotensin II-induced apoptosis in human endothelial cells is inhibited by adiponectin through restoration of the association between endothelial nitric oxide synthase and heat shock protein 90, FEBS Lett, 574, 106, 10.1016/j.febslet.2004.08.012 Shibata, 2005, Adiponectin protects against myocardial ischemia–reperfusion injury through AMPK- and COX-2-dependent mechanisms, Nat Med, 11, 1096, 10.1038/nm1295 Kojima, 2003, The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction, Heart, 89, 667, 10.1136/heart.89.6.667 Bolli, 2002, Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning, Cardiovasc Res, 55, 506, 10.1016/S0008-6363(02)00414-5 Camitta, 2001, Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning, Circulation, 104, 2453, 10.1161/hc4401.098429 Xiao, 2004, Prostaglandin E2 protects the heart from ischemia–reperfusion injury via its receptor subtype EP4, Circulation, 109, 2462, 10.1161/01.CIR.0000128046.54681.97 Hohlfeld, 2000, Reduction of infarct size by selective stimulation of prostaglandin EP(3)receptors in the reperfused ischemic pig heart, J Mol Cell Cardiol, 32, 285, 10.1006/jmcc.1999.1072 Ilercil, 2001, Relationship of impaired glucose tolerance to left ventricular structure and function: The Strong Heart Study, Am Heart J, 141, 992, 10.1067/mhj.2001.115302 Rutter, 2003, Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study, Circulation, 107, 448, 10.1161/01.CIR.0000045671.62860.98 Shibata, 2004, Adiponectin-mediated modulation of hypertrophic signals in the heart, Nat Med, 10, 1384, 10.1038/nm1137 Liao, 2005, Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism, Cardiovasc Res, 67, 705, 10.1016/j.cardiores.2005.04.018 Fujioka, 2006, Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart, Am J Physiol Heart Circ Physiol, 290, H2409, 10.1152/ajpheart.00987.2005 Tian, 2001, Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy, Circulation, 104, 1664, 10.1161/hc4001.097183 Maeda, 2002, Diet-induced insulin resistance in mice lacking adiponectin/ACRP30, Nat Med, 8, 731, 10.1038/nm724 Nawrocki, 2006, Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists, J Biol Chem, 281, 2654, 10.1074/jbc.M505311200 Kubota, 2002, Disruption of adiponectin causes insulin resistance and neointimal formation, J Biol Chem, 277, 25863, 10.1074/jbc.C200251200 Ma, 2002, Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin, J Biol Chem, 277, 34658, 10.1074/jbc.C200362200 Berg, 2001, The adipocyte-secreted protein Acrp30 enhances hepatic insulin action, Nat Med, 7, 947, 10.1038/90992 Fruebis, 2001, Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice, Proc Natl Acad Sci U S A, 98, 2005, 10.1073/pnas.041591798 Tomas, 2002, Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation, Proc Natl Acad Sci U S A, 99, 16309, 10.1073/pnas.222657499 Yamauchi, 2002, Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase, Nat Med, 8, 1288, 10.1038/nm788 Wu, 2003, Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes, Diabetes, 52, 1355, 10.2337/diabetes.52.6.1355 Satoh, 2005, Adenovirus-mediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats, Diabetes, 54, 1304, 10.2337/diabetes.54.5.1304 Combs, 2004, A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity, Endocrinology, 145, 367, 10.1210/en.2003-1068 Yamauchi, 2003, Cloning of adiponectin receptors that mediate antidiabetic metabolic effects, Nature, 423, 762, 10.1038/nature01705 Ryo, 2004, Adiponectin as a biomarker of the metabolic syndrome, Circ J, 68, 975, 10.1253/circj.68.975 Hotta, 2000, Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients, Arterioscler Thromb Vasc Biol, 20, 1595, 10.1161/01.ATV.20.6.1595 Lindsay, 2002, Adiponectin and development of type 2 diabetes in the Pima Indian population, Lancet, 360, 57, 10.1016/S0140-6736(02)09335-2 Spranger, 2003, Adiponectin and protection against type 2 diabetes mellitus, Lancet, 361, 226, 10.1016/S0140-6736(03)12255-6 Snehalatha, 2003, Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians, Diabetes Care, 26, 3226, 10.2337/diacare.26.12.3226 Choi, 2004, Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans, Clin Endocrinol (Oxf), 61, 75, 10.1111/j.1365-2265.2004.02063.x Yamamoto, 2004, Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population, J Clin Endocrinol Metab, 89, 87, 10.1210/jc.2003-031163 Shetty, 2004, Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes, Diabetes Care, 27, 2450, 10.2337/diacare.27.10.2450 Adamczak, 2003, Decreased plasma adiponectin concentration in patients with essential hypertension, Am J Hypertens, 16, 72, 10.1016/S0895-7061(02)03197-7 Iwashima, 2004, Hypoadiponectinemia is an independent risk factor for hypertension, Hypertension, 43, 1318, 10.1161/01.HYP.0000129281.03801.4b Kumada, 2003, Association of hypoadiponectinemia with coronary artery disease in men, Arterioscler Thromb Vasc Biol, 23, 85, 10.1161/01.ATV.0000048856.22331.50 Nakamura, 2004, Implications of plasma concentrations of adiponectin in patients with coronary artery disease, Heart, 90, 528, 10.1136/hrt.2003.011114 von Eynatten, 2006, Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men, J Am Coll Cardiol, 47, 2124, 10.1016/j.jacc.2006.02.033 Zoccali, 2002, Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease, J Am Soc Nephrol, 13, 134, 10.1681/ASN.V131134 Pischon, 2004, Plasma adiponectin levels and risk of myocardial infarction in men, JAMA, 291, 1730, 10.1001/jama.291.14.1730 Schulze, 2005, Adiponectin and future coronary heart disease events among men with type 2 diabetes, Diabetes, 54, 534, 10.2337/diabetes.54.2.534 Lindsay, 2005, Adiponectin and coronary heart disease: the Strong Heart Study, Arterioscler Thromb Vasc Biol, 25, e15, 10.1161/01.ATV.0000153090.21990.8c Lawlor, 2005, Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women, J Clin Endocrinol Metab, 90, 5677, 10.1210/jc.2005-0825 Sattar, 2006, Adiponectin and coronary heart disease: a prospective study and meta-analysis, Circulation, 114, 623, 10.1161/CIRCULATIONAHA.106.618918 Ridker, 2003, High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention, Am J Cardiol, 92, 17K, 10.1016/S0002-9149(03)00774-4 Laaksonen, 2004, C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men, Diabetologia, 47, 1403, 10.1007/s00125-004-1472-x Mendall, 1996, C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study, BMJ, 312, 1061, 10.1136/bmj.312.7038.1061 Yudkin, 1999, C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?, Arterioscler Thromb Vasc Biol, 19, 972, 10.1161/01.ATV.19.4.972 Ouchi, 2003, Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue, Circulation, 107, 671, 10.1161/01.CIR.0000055188.83694.B3 Engeli, 2003, Association between adiponectin and mediators of inflammation in obese women, Diabetes, 52, 942, 10.2337/diabetes.52.4.942 Mantzoros, 2005, Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes, J Clin Endocrinol Metab, 90, 4542, 10.1210/jc.2005-0372 Krakoff, 2003, Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian, Diabetes Care, 26, 1745, 10.2337/diacare.26.6.1745 Matsubara, 2003, Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation, Eur J Endocrinol, 148, 657, 10.1530/eje.0.1480657 Matsushita, 2006, Inverse association between adiponectin and C-reactive protein in substantially healthy Japanese men, Atherosclerosis, 188, 184, 10.1016/j.atherosclerosis.2005.10.031 von Eynatten, 2006, Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease, Clin Chem, 52, 853, 10.1373/clinchem.2005.060509 Blake, 2001, Novel clinical markers of vascular wall inflammation, Circ Res, 89, 763, 10.1161/hh2101.099270 Maeda, 2001, PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein, Diabetes, 50, 2094, 10.2337/diabetes.50.9.2094 Kappes, 2000, Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes, Horm Metab Res, 32, 548, 10.1055/s-2007-978684 Fasshauer, 2003, Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes, Biochem Biophys Res Commun, 301, 1045, 10.1016/S0006-291X(03)00090-1 Ziccardi, 2002, Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year, Circulation, 105, 804, 10.1161/hc0702.104279 Yang, 2001, Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin, J Clin Endocrinol Metab, 86, 3815, 10.1210/jc.86.8.3815 Yu, 2002, The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects, Diabetes, 51, 2968, 10.2337/diabetes.51.10.2968 Yang, 2002, Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients, Diabetes Care, 25, 376, 10.2337/diacare.25.2.376 Combs, 2002, Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization, Endocrinology, 143, 998, 10.1210/en.143.3.998 Kubota, 2006, Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways, J Biol Chem, 281, 8748, 10.1074/jbc.M505649200 Marx, 2003, Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease, Circulation, 107, 1954, 10.1161/01.CIR.0000069272.06194.91 Haffner, 2002, Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus, Circulation, 106, 679, 10.1161/01.CIR.0000025403.20953.23 Katsuki, 2000, Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes, Diabetes Obes Metab, 2, 189, 10.1046/j.1463-1326.2000.00072.x Wittchen, 2006, Genomic expression profiling of human inflammatory cardiomyopathy (DCMi) suggests novel therapeutic targets, J Mol Med